@article{MRA, author = {Kei Suzuki and Hideo Wada and Kaoru Ikejiri and Asami Ito and Takeshi Matsumoto and Shine Tone and Masahiro Hasegawa and Motomu Shimaoka and Toshiaki Iba and Hiroshi Imai}, title = {A Prolongation of Peak Time but an Elevated Peak Height of a Clot Wave Form Analysis in Severe Coronavirus Disease 2019}, journal = {Medical Research Archives}, volume = {11}, number = {1}, year = {2023}, keywords = {}, abstract = {Objective: As coronavirus disease 2019 (COVID-19) is frequently associated with thrombotic diseases, the hemostatic abnormalities in cases of COVID-19 have attracted attention. This study examined the hemostatic abnormalities in patients with severe COVID-19. Methods: Hemostatic abnormalities were examined based on the activated partial thromboplastin time (APTT) and small amount of tissue factor-induced FIX activation (sTF/FIXa) using a clot waveform analysis (CWA). The anti-Xa activity, C5b-9 and ADAMTS 13 values were also examined in these patients. Results: CWA-APTT and CWA-sTF/FIXa showed that the peak times were prolonged, but peak heights were increased before anticoagulant therapy. The parameters of the CWA-APTT and CWA-sTF/FIXa were not correlated with the anti-Xa activity. The peak times of the CWA-sTF/FIXa were significantly longer in non-survivors than survivors. Although the plasma levels of C5b-9 and ADAMTS13 activity were markedly decreased in severe COVID-19 patients, there were no significant differences in C5b-9 levels or ADAMTS-13 activity between survivors and non-survivors. Conclusions: The CWA showed the marked hemostatic abnormalities and hypercoagulability in COVID-19 patients, and anticoagulant therapy might not be monitored by routine APTT.}, issn = {2375-1924}, doi = {10.18103/mra.v11i1.3549}, url = {https://esmed.org/MRA/mra/article/view/3549} }